Stock Price Quote

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE1943.1061.4 (+3.26 %)
PREV CLOSE ( ) 1881.70
OPEN PRICE ( ) 1888.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18731
TODAY'S LOW / HIGH ( )1888.45 1963.15
52 WK LOW / HIGH ( )1228 2649.95
NSE1946.6066.8 (+3.55 %)
PREV CLOSE( ) 1879.80
OPEN PRICE ( ) 1890.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1946.60 (91)
VOLUME 120032
TODAY'S LOW / HIGH( ) 1890.45 1962.35
52 WK LOW / HIGH ( )1227 2524
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924
Management Info
R S Karnad - Chairman Bhushan Akshikar - Managing Director
Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

13Mar Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
06Mar GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
27Feb Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
23Feb GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
21Feb Glaxosmithkline Pharmaceuticals inform
Glaxosmithkline Pharmaceuticals has informed that pursuant to Regulation..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit454.9000000000016077.5
Gross Profit 651.100000000001 8323.8
Operating Profit 2458.59009.3
Net Sales 8049.832163.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
RPG Life Sciences (BSE)
peergroup  1530.20 (3.92%)
M.Cap ( in Cr)2530.80

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 4.5%
FI/BANKS/INSURANCE 4.04%
NON-INSTITUTION 13.43%
GOVERNMENT 0.01%
FII 0%

About Glaxosmithkline Pharmaceuticals Ltd.

Glaxosmithkline Pharmaceuticals Ltd. was incorporated in the year 1924. Its today's share price is 1943.1. Its current market capitalisation stands at Rs 32917.29 Cr. In the latest quarter, company has reported Gross Sales of Rs. 35327.42 Cr and Total Income of Rs.33178.56 Cr. The company's management includes Juby Chandy, Manu Anand, Bhushan Akshikar, Ajay Nadkarni, S Williams, D Sundaram, A N Roy, S Maheshwari, PV Bhide, R S Karnad.

It is listed on the BSE with a BSE Code of 500660 , NSE with an NSE Symbol of GLAXO and ISIN of INE159A01016. It's Registered office is at Gsk House, Dr. Annie Besant Road,Worli,Mumbai-400030, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Lovelock & Lewes, Price Waterhouse & Co, Price Waterhouse & Co Bangalore LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.